The Business of Biotech #podcast features Jeff Stein discussing Cidara Therapeutics’s manufacturing approach, anticipated to yield a low-cost alternative to standards of care in multiple #antiviral indications. #businessofbiotech $CDT bit.ly/37IEx8D

Monday's episode of the Business of Biotech podcast will feature Amolyt Pharma CEO Thierry Abribat dishing on his company's clinical preparations. Meanwhile, catch up on recent talks on #artificialintelligence in #genomicmedicine w…lnkd.in/e3yJ46Y lnkd.in/eur__HP

In recognition of #internationalwomensday2021, revisit the remarkable women who have joined me on the Business of Biotech podcast, including Edith A. Perez, MD, Smital Shah, Loretta Itri, Kavitha Iyer Rodrigues, Leslie J Williams, a…lnkd.in/e8CwdNc lnkd.in/eur__HP

Fresh on the heels of its #hypoparathyroidism candidate's foray into phase 1 clinical trials, we're joined by Amolyt Pharma founder and CEO Thierry Abribat for a deep dive into his company's pre-clinical preparation, including fina…lnkd.in/e7GExZq lnkd.in/ePPtfGB

As the CAR T-cell therapy market expands at a fast clip, the dynamic of the "payer layer" is must-follow for the leaders of emerging cell therapy companies. Thanks to Clarivate primary research manager Chris Lewis for sharing this…lnkd.in/ejeHSGM lnkd.in/eJSrcek

With backing from heavyweights like Dr. Peter H. Diamandis and @tonyrobbins, Elevian, Inc. CEO Dr. Mark Allen seeks to release the power of a naturally-occurring molecule known as growth differentiation factor 11 to combat age-rela…lnkd.in/etiNew9 lnkd.in/eCdXsqF

Tune on Monday, March 29, 2021, for the #businessofbiotech #podcast. #Precigen's Helen Sabzevari joins Matthew Pillar to discuss changing the CAR-T complexity paradigm with an overnight manufacturing process to affect patients in urgent need of timely therapy. $PGEN

This week on The Business of Biotech, Rezolute, Inc. CEO Nevan Charles Elam shares the company's rationale for pursuing congenital #hyperinsulinism and #diabetic macular edema therapeutics by leveraging monoclonal antibodies and di…lnkd.in/eQy74Ce lnkd.in/emcXz6T

"Most people who must climb a ladder do not manage the severity of falling off a ladder. They manage the risk event by taking steps to decrease the likelihood of a fall," says Mark F. Witcher, Ph.D. as he argues to replace RPN with…lnkd.in/ezA_dUn lnkd.in/eUfFFQw

SOTIO CEO Radek Spisek, Ph.D. manages the support of 14 #clinicaltrials for its pipeline of #oncology therapeutics. Learn how we does it on this week's #businessofbiotech via BioProcess Online. lnkd.in/estkvRs

Nearly 85% of 18-to-65 year-olds will have at least one strain of #HPV at some point in their life. The #hpvvaccine prevents a host of #cancers, but for whole generations, it came too late. Cue Biopharma CEO Daniel Passeri shares w…lnkd.in/d_Z6yC9 lnkd.in/da4b2nk

Looking for #biotechnology incubation/accelerator space? Whether or not you're in the Valley, this BioProcess Online talk with BioCube-SJ CEO Anthony Gonzalez will give you an idea what good looks like. #biopharma #startups lnkd.in/e2aeQg4

How close are we to manufacturing autologous cell therapies in hospital cleanrooms? Clinical-stage #celltherapy company Precigen and its CEO Dr. Helen Sabzevari say closer than you might think. #businessofbiotech via BioProcess Online bioprocessonline.com/doc/decentrali…

Ease into the weekend with the latest episode of #businessofbiotech featuring regulatory environment musings with bluebird bio's Scott Cleve, then tune in Monday for insight from Organicell Regenerative Medicine's Mari Mitrani, MD, PhD and D…lnkd.in/evEiMAg lnkd.in/eWU_VNQ

On this fresh episode of the #businessofbiotech podcast, learn how Organicell CSO Mari Mitrani, MD, PhD and Lab Director Dr. Michael Bellio leverage #bioinformatics to discover the therapeutic potential of perinatal tissue-secreted #exosomes. bioprocessonline.com/doc/digital-tr…

On the new #BusinessOfBiotech #podcast episode, CEO Dr. @CarolineLoew and @MattPillar discussed the potential of our in-vivo, bioengineered, tunable sensors for diagnostic and prognostic purposes in protease-mediated diseases like #NASH. Listen now: bit.ly/3vFfnBN

GSK Senior Clinical Development Manager Michael Mehler shares how GlaxoSmithKline navigates the competition for talent—and how #clinicalresearch directly informs the company's #HR requirements—on this fresh episode of the #business…lnkd.in/guyk_HW lnkd.in/gej6Q8m

Want to know what process intensification is, the results it drives, the challenges it presents, and how to implement it in your upstream #bioprocessing environment? Join Sonnet BioTherapeutics, Inc. CTO Susan Dexter, single-use an…lnkd.in/eae4t3c lnkd.in/edUbNWa

I really leaned in to Allan Shaw's #startup financing knowledge base for this candid conversation on the ins and outs of a special purpose acquisition company, or #SPAC, as a biopharma finance vehicle. He was definitely the man to ask. Via BioProcess O…lnkd.in/eMmy_3N

Retailers increasingly not accepting #cash in the US market. The excuse is a lack of circulation of cash due to #COVID19 does this explanation make sense?